Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Mirum Pharmaceuticals, Inc.

NASDAQ: MIRM · Life Sciences · 9 alerts · CIK 1759425

Mirum Pharmaceuticals, Inc. stories on ALFA USA NewsRead the news →
Share price
$91.58Close, Nov 16
Market cap
$5.98B
Shares outstanding
65.28MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Mirum Pharmaceuticals, Inc. filings on SEC EDGAR ↗

7:42 AM ET 8-K
Clinical Trial Data

Mirum Pharmaceuticals Clinical Trial Data

Mirum Pharmaceuticals announced that its Phase 3 AZURE-4 study of brelovitug met its primary endpoint in patients with chronic hepatitis delta virus (HDV). The study showed that 59% of patients on the 300 mg weekly dose achieved the combined endpoint of virologic response and ALT normalization compared to 0% in the delayed-treatment arm. This data, alongside results from the AZURE-1 study, will form the basis of the company's U.S. registration package for brelovitug.

4:47 PM ET 8-K
Clinical Trial Data

Mirum Pharmaceuticals Clinical Trial Data

Mirum Pharmaceuticals announced positive results from Cohort 2 of its pivotal PROGRESS study evaluating ATEBRIOZ (zilurgisertib) in pediatric patients aged 6 to <12 with fibrodysplasia ossificans progressiva (FOP). The study met its endpoints with a significant reduction in total heterotopic ossification lesion volume and improved joint mobility compared to placebo, supporting a planned sNDA submission in the first half of 2027.

8:09 AM ET 8-K
Clinical Trial Data

Mirum Pharmaceuticals Clinical Trial Data

Mirum Pharmaceuticals announced positive topline results from its Phase 3 EXPAND study of LIVMARLI (maralixibat) for ultra-rare cholestatic liver diseases, including biliary atresia. The study met its primary endpoint for pruritus improvement and all five secondary endpoints with statistical significance. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in the first half of 2027 based on these results.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.